Skip to Main Content

Paper Details

PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.
Cancer Discov
14
2022
Cancer, DNA methyltransferase 1, DNMT, DNMT1, MPNST, PKR, PRC2, PRC2-dependent cancers, PRC2-loss cancer, Polycomb repressive complex 2, antitumor, antitumorigenic cell, cancer, cancers, double-stranded RNA, high-grade malignant peripheral nerve sheath tumor, protein kinase R, retrotransposons, sarcoma, tumor
Author NameAffiliation
Charles M RudinMemorial Sloan Kettering Cancer Center
Charles M RudinMemorial Sloan Kettering Cancer Center
Richard KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center
Richard KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center
Cristina R AntonescuMemorial Sloan Kettering Cancer Center
Cristina R AntonescuMemorial Sloan Kettering Cancer Center
Deyou ZhengAlbert Einstein College of Medicine
Deyou ZhengAlbert Einstein College of Medicine
Deyou ZhengAlbert Einstein College of Medicine
Yu ChenMemorial Sloan Kettering Cancer Center
Yu ChenMemorial Sloan Kettering Cancer Center
Yu ChenCornell University
Yu ChenMemorial Sloan Kettering Cancer Center
Yu ChenWeill Cornell Medical College
  • 1 - 14

Datasets

Release 1.2